Cargando…

Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?

INTRODUCTION: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are a unique class of drugs currently used in the management of type 2 diabetes (T2D). There are emerging data from cardiovascular outcome trials confirming renal and heart failure benefits of these drugs independent of glucose lower...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinton, William, Feher, Michael, Munro, Neil, de Lusignan, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434824/ https://www.ncbi.nlm.nih.gov/pubmed/32671574 http://dx.doi.org/10.1007/s13300-020-00878-y

Ejemplares similares

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
por: Hinton, William, et al.
Publicado: (2021)

How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol
por: Hinton, William, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)
por: Feher, Michael, et al.
Publicado: (2022)

Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care
por: Hinton, W., et al.
Publicado: (2020)

Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
por: Hinton, William, et al.
Publicado: (2018)

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
por: McGovern, Andrew, et al.
Publicado: (2017)

Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol)
por: de Lusignan, Simon, et al.
Publicado: (2019)

Obstructive sleep apnoea in Type 2 diabetes mellitus: increased risk for overweight as well as obese people included in a national primary care database analysis
por: Feher, M., et al.
Publicado: (2019)

Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
por: Hinton, William, et al.
Publicado: (2019)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
por: Saad, Muhammad, et al.
Publicado: (2018)

Improving the Management of Atrial Fibrillation in General Practice: Protocol for a Mixed Methods Study
por: de Lusignan, Simon, et al.
Publicado: (2020)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
por: Feher, Michael, et al.
Publicado: (2021)

The Effect of the COVID-19 Pandemic on Glycemic Monitoring and Other Processes of Care for Type 2 Diabetes: Protocol for a Retrospective Cohort Study
por: Mathew, Mekha, et al.
Publicado: (2022)

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
por: Joshi, Shruti S, et al.
Publicado: (2021)

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
por: Angelini, Gianmarco, et al.
Publicado: (2021)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
por: Rosano, Giuseppe, et al.
Publicado: (2020)

Correction: Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Publicado: (2021)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
por: Oh, Jaewon, et al.
Publicado: (2021)

Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
por: Moady, Gassan, et al.
Publicado: (2023)

Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism
por: Hinton, William, et al.
Publicado: (2020)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
por: Alkagiet, Stelina, et al.
Publicado: (2020)

Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure
por: Yazaki, Mayu, et al.
Publicado: (2019)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
por: Liang, Bo, et al.
Publicado: (2022)

Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials
por: Kato, Eri Toda, et al.
Publicado: (2020)

Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
por: Shen, Xizi, et al.
Publicado: (2022)

Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Sodium‐glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia
por: Tang, Wen‐Jing, et al.
Publicado: (2023)

Hepatitis A Vaccination Coverage Among People With Chronic Liver Disease in England (HEALD): Protocol for a Retrospective Cohort Study
por: Meza-Torres, Bernardo, et al.
Publicado: (2023)

The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure
por: Sharma, Abhinav, et al.
Publicado: (2019)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q5e7h59rgulgklij1aeughknla